Skip to main content

Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium.

Publication ,  Journal Article
Charlton, ME; Stitzenberg, KB; Lin, C; Schlichting, JA; Halfdanarson, TR; Juarez, GY; Pendergast, JF; Chrischilles, EA; Wallace, RB
Published in: J Oncol Pract
July 2015

PURPOSE: Many patients do not receive guideline-recommended neoadjuvant chemoradiotherapy for resectable rectal cancer. Little is known regarding long-term quality of life (QOL) associated with various treatment approaches. Our objective was to determine patient characteristics and subsequent QOL associated with treatment approach. METHODS: Our study was a geographically diverse population- and health system-based cohort study that included adults age 21 years or older with newly diagnosed stage II/III rectal cancer who were recruited from 2003 to 2005. Eligible patients were contacted 1 to 4 months after diagnosis and asked to participate in a telephone survey and to consent to medical record review, with separate follow-up QOL surveys conducted 1 and 7 years after diagnosis. RESULTS: Two hundred thirty-nine patients with stage II/III rectal cancer were included in this analysis. Younger age (< 65 v ≥ 65 years: odds ratio, 2.49; 95% CI, 1.33 to 4.65) was significantly associated with increased odds of receiving neoadjuvant or adjuvant chemoradiotherapy. The adjuvant chemoradiotherapy group had significantly worse mean EuroQol-5D (range, 0 to 1) and Short Form-12 physical health component scores (standardized mean, 50) at 1-year follow-up than the neoadjuvant chemoradiotherapy group (0.75 v 0.85; P = .002; 37.2 v 43.3; P = .01, respectively) and the group that received only one or neither form of treatment (0.75 v 0.85; P = .02; 37.2 v 45.1; P = .008, respectively). CONCLUSION: Neoadjuvant treatment may result in better QOL and functional status 1 year after diagnosis. Further evaluation of patient and provider reasons for not pursuing neoadjuvant therapy is necessary to determine how and where to target process improvement and/or education efforts to ensure that patients have access to recommended treatment options.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Oncol Pract

DOI

EISSN

1935-469X

Publication Date

July 2015

Volume

11

Issue

4

Start / End Page

e476 / e486

Location

United States

Related Subject Headings

  • Time Factors
  • Survivors
  • Surveys and Questionnaires
  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Quality of Life
  • Patient Education as Topic
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Charlton, M. E., Stitzenberg, K. B., Lin, C., Schlichting, J. A., Halfdanarson, T. R., Juarez, G. Y., … Wallace, R. B. (2015). Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. J Oncol Pract, 11(4), e476–e486. https://doi.org/10.1200/JOP.2015.004564
Charlton, Mary E., Karyn B. Stitzenberg, Chi Lin, Jennifer A. Schlichting, Thorvardur R. Halfdanarson, Grelda Yazmin Juarez, Jane F. Pendergast, Elizabeth A. Chrischilles, and Robert B. Wallace. “Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium.J Oncol Pract 11, no. 4 (July 2015): e476–86. https://doi.org/10.1200/JOP.2015.004564.
Charlton ME, Stitzenberg KB, Lin C, Schlichting JA, Halfdanarson TR, Juarez GY, et al. Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. J Oncol Pract. 2015 Jul;11(4):e476–86.
Charlton, Mary E., et al. “Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium.J Oncol Pract, vol. 11, no. 4, July 2015, pp. e476–86. Pubmed, doi:10.1200/JOP.2015.004564.
Charlton ME, Stitzenberg KB, Lin C, Schlichting JA, Halfdanarson TR, Juarez GY, Pendergast JF, Chrischilles EA, Wallace RB. Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. J Oncol Pract. 2015 Jul;11(4):e476–e486.

Published In

J Oncol Pract

DOI

EISSN

1935-469X

Publication Date

July 2015

Volume

11

Issue

4

Start / End Page

e476 / e486

Location

United States

Related Subject Headings

  • Time Factors
  • Survivors
  • Surveys and Questionnaires
  • Rectal Neoplasms
  • Radiotherapy, Adjuvant
  • Quality of Life
  • Patient Education as Topic
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Neoadjuvant Therapy